IO Converse presents: Founder insights - Two UCL academics’ mission to supercharge mass spectrometry

Founder insights: Two UCL academics’ mission to supercharge mass spectrometry

Join us for the next IO Converse session on 2nd July, 12.30-2pm to hear about UCL spinout Guilford Street Labs (GSL)’s mission to elevate care for patients with rare, cardiac and neurodegenerative diseases.  

Professor Kevin Mills and Dr. Tomas Baldwin from GSL join UCLB’s Senior Business Manager Dr. Caitriona O’Rourke to uncover their journey leveraging mass spectrometry’s precision and supercharging it with machine learning. 

Comprising top clinicians and scientists from UCL, GSL, formed from the Translational Mass Spectrometry group at the world-renowned UCL & GOSH Institute of Child Health, are set to revolutionise 21st-century diagnostic testing.  

Secure you spot now to discover the story behind a company aiming to reshape the future of healthcare. 

A light lunch will be served. 

 

GSL’s offering 

Harnessing the capabilities of machine learning-driven mass spectrometry, GLS delivers exceptionally sensitive and precise biomarker assays. Its comprehensive services span the entirety of the clinical journey, encompassing drug discovery, clinical trials, diagnostics, and ongoing patient monitoring.  

GSL’s expertise extends to the analysis of protein, lipid, and metabolite biomarkers, individually or in its proprietary biomarker panels.  

Secure your spot now and be part of this exciting conversation that could spark your own innovative ideas!  

 

Speaker Bio:

Dr Tomas Baldwin is a research fellow within the Translational Mass Spectrometry team at the UCL & GOS Institute of Child Health. His research involves biomarker discovery and translation for a wide range of indications, particularly in paediatric rare diseases. Tom’s primary research goal is the development of new and innovative methodologies for assessing immunogenicity in patients receiving protein therapeutics and AAV gene therapies. Dr Baldwin is a co-founder and CEO of the UCL spin-out company, Guilford Street Laboratories.

Professor Kevin Mills is the Head of the Translational and Clinical Omics Group at UCL based at the GOSH ICH. His research group’s aim is to bring together state-of-the-art technology with AI/Machine Learning to find new drug targets, disease mechanisms, identify new biomarkers and develop new and more precise tests. He is also Chief Scientific Officer for Guilford Street Laboratories.

_______________________________________________________________________________

This talk is brought to you by UCLB’s IO Converse, a regular networking event for academics to meet and discuss topical questions around the value of bringing academic research ‘from university to market’ through commercialisation with UCLB.

By attending these sessions academics can meet experts from UCL Business, ask questions, exchange ideas and be inspired to look for opportunities for market impact from their own research portfolios.

These sessions are open to academics and research staff/fellows only.

Register